| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
Antimicrobial agent-14 targets bacterial cells, with specific activity against Campylobacter species. While the precise molecular target has not been fully elucidated in the available literature, the compound belongs to the benzylthiophenesulfonamide class, which is known to interfere with essential bacterial processes. Its narrow-spectrum activity suggests a specific interaction with a target that is present in Campylobacter but not in other bacterial species. The compound’s mechanism of action is believed to involve disruption of key microbial structures or metabolic pathways essential for bacterial survival and growth.
|
|---|---|
| ln Vitro |
Antimicrobial agent-14 (compound 10) minimum inhibitory concentration (MIC) against Campylobacter jejuni 81-176 is more than 200 μM [1].
In vitro studies have demonstrated that Antimicrobial agent-14 exhibits potent antibacterial activity against Campylobacter coli ATCC33559 with a minimum inhibitory concentration (MIC) of 200 μM. Against Campylobacter jejuni 81-176, the compound shows an MIC of greater than 200 μM. These findings indicate that the compound is more effective against C. coli than against C. jejuni, suggesting species-specific activity. The compound’s antibacterial efficacy has been established through standardized broth microdilution assays, and it has been cited in peer-reviewed literature as a novel narrow-spectrum agent for controlling Campylobacter. |
| ln Vivo |
No detailed in vivo activity data for Antimicrobial agent-14 has been published in the available literature. The compound has been primarily characterized in vitro as a research tool for studying Campylobacter infections. Its narrow-spectrum activity and MIC values suggest that it could have potential for in vivo applications, but further studies would be needed to evaluate its efficacy in animal models of Campylobacter infection. The compound’s activity against foodborne pathogens makes it a candidate for further investigation in gastrointestinal infection models.
|
| Enzyme Assay |
The antimicrobial activity of Antimicrobial agent-14 can be assessed using standardized in vitro susceptibility testing methods, such as the broth microdilution assay as recommended by the Clinical and Laboratory Standards Institute (CLSI). In a typical assay, serial two-fold dilutions of the compound are prepared in cation-adjusted Mueller-Hinton broth in 96-well microtiter plates. Bacterial suspensions are adjusted to a 0.5 McFarland standard and added to each well. The plates are incubated at 37°C for 18-24 hours under microaerophilic conditions for Campylobacter species. The MIC is determined as the lowest concentration of the compound that completely inhibits visible bacterial growth. Quality control strains are included to validate the assay.
|
| Cell Assay |
The in vitro antibacterial activity of Antimicrobial agent-14 is assessed using Campylobacter coli ATCC33559 and Campylobacter jejuni 81-176 as test organisms. Bacterial cultures are grown on appropriate agar media under microaerophilic conditions at 37°C for 24-48 hours. Colonies are suspended in broth to achieve a standardized inoculum. The compound is dissolved in DMSO and diluted to working concentrations. The MIC is determined using the broth microdilution method in 96-well plates. The plates are incubated under microaerophilic conditions, and growth is assessed by measuring optical density at 600 nm or by visual inspection. The compound shows an MIC of 200 μM against C. coli ATCC33559.
|
| Animal Protocol |
No detailed in vivo animal model data for Antimicrobial agent-14 has been published in the available literature. The compound has not been evaluated in animal models of Campylobacter infection to assess its in vivo efficacy or pharmacokinetic properties. Future studies may involve the use of mouse or chicken models of Campylobacter colonization to evaluate the compound’s ability to reduce bacterial burden in the gastrointestinal tract. Such studies would be essential to confirm the compound’s in vivo antibacterial activity and to assess its potential for therapeutic development.
|
| ADME/Pharmacokinetics |
No detailed pharmacokinetic data for Antimicrobial agent-14 has been published in the available literature. The compound has a molecular weight of 277.75 g/mol and a LogP of 2.52, suggesting moderate lipophilicity. It is soluble in DMSO at 125 mg/mL (450.05 mM). The compound has a density of 1.5±0.1 g/cm³, a boiling point of 427.6±55.0 °C, and a flash point of 212.4±31.5 °C. Further studies would be needed to characterize the absorption, distribution, metabolism, and excretion (ADME) properties of Antimicrobial agent-14, including oral bioavailability, plasma protein binding, clearance, and half-life.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data for Antimicrobial agent-14 has been published in the available literature. As a research compound with narrow-spectrum antibacterial activity, its safety profile has not been comprehensively evaluated. The compound is intended for research use only and is not for human or veterinary therapeutic use. The benzylthiophenesulfonamide class of compounds may have specific toxicity profiles that would need to be assessed in future studies. Comprehensive toxicology studies, including acute and chronic toxicity testing in multiple species, would be required to evaluate the safety profile of Antimicrobial agent-14 for potential therapeutic development.
|
| References |
[1]. Deblais L, et, al. Novel narrow spectrum benzyl thiophene sulfonamide derivatives to control Campylobacter. J Antibiot (Tokyo). 2019 Jul;72(7):555-565.
|
| Additional Infomation |
Antimicrobial agent-14 (5-chloro-N-(furan-2-ylmethyl)thiophene-2-sulfonamide) is a benzylthiophenesulfonamide analogue with antibacterial activity against Campylobacter species. The compound has an MIC of 200 μM against Campylobacter coli ATCC33559 and an MIC of >200 μM against Campylobacter jejuni 81-176. It is a research chemical used for the study of bacterial foodborne gastroenteritis. The compound has a molecular weight of 277.75 g/mol, a molecular formula of C9H8ClNO3S2, and a purity of ≥98%. It is typically stored as a powder at -20°C and is soluble in DMSO. The compound has been cited in a publication in the Journal of Antibiotics.
|
| Molecular Formula |
C9H8CLNO3S2
|
|---|---|
| Molecular Weight |
277.75
|
| Exact Mass |
276.963
|
| CAS # |
380576-68-1
|
| PubChem CID |
2353996
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
427.6±55.0 °C at 760 mmHg
|
| Flash Point |
212.4±31.5 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.609
|
| LogP |
2.52
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
16
|
| Complexity |
330
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1(S(NCC2=CC=CO2)(=O)=O)SC(Cl)=CC=1
|
| InChi Key |
UOVJGVLNKRNDLY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H8ClNO3S2/c10-8-3-4-9(15-8)16(12,13)11-6-7-2-1-5-14-7/h1-5,11H,6H2
|
| Chemical Name |
5-chloro-N-(furan-2-ylmethyl)thiophene-2-sulfonamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 125 mg/mL (450.05 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6004 mL | 18.0018 mL | 36.0036 mL | |
| 5 mM | 0.7201 mL | 3.6004 mL | 7.2007 mL | |
| 10 mM | 0.3600 mL | 1.8002 mL | 3.6004 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
